checkAd
    Startseite > Aktien > Seres Therapeutics > Nachrichten
    Seres Therapeutics Aktie
    0,7620
     
    EUR
    +8,39 %
    +0,0590 EUR
    Letzter Kurs 18:52:37 Tradegate
    0,7554
     
    EUR
    10.600 STK
    Geldkurs 20:22:45
    0,7784
     
    EUR
    10.280 STK
    Briefkurs 20:22:45
    ISIN: US81750R1023 · WKN: A14VXX · SYM: 1S9 · USA

    Neueste Nachrichten

    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    07.06.24 · globenewswire · Seres Therapeutics
    Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestlé Health Science
    06.06.24 · globenewswire · Seres Therapeutics
    Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
    08.05.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    06.05.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
    06.05.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
    09.04.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    28.03.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    19.03.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
    28.02.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
    27.02.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
    26.02.24 · Business Wire (engl.) · Seres Therapeutics
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    17.01.24 · Business Wire (engl.) · Seres Therapeutics